Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
批准号:
8323313
负责人:
Mehmet Kesimer
金额:
$37.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-22 至 2015-06-30
关键词:
AlveolarAncillary StudyBiochemicalBiological AssayBiological MarkersBronchoscopyChronic Obstructive Airway DiseaseChronic lung diseaseClassificationClinical TrialsCoughingCoupledDetectionElectron MicroscopyEnvironmentEnzyme-Linked Immunosorbent AssayExcisionFutureGelGel ChromatographyGlandGoalsHypertrophyInfectionInflammationKnowledgeLaboratoriesLasersMUC5AC geneMUC5B geneMass Spectrum AnalysisMeasuresMethodsModalityMolecularMorbidity - disease rateMucinsMucociliary ClearanceMucous body substanceNatureObservational StudyObstructionOutcome MeasureParticulatePathogenesisPathologyPatientsPeptide HydrolasesPlayPredispositionPropertyProtease InhibitorProteinsProteolysisProteomeProteomicsPublishingPulmonary EmphysemaRefractometryRelative (related person)RheologyRoleSamplingSepharoseSmokerSmokingSolventsSourceSputumStructureTestingTherapeuticTherapeutic InterventionToxinUltracentrifugationWestern Blottingbasedesigndisease characteristicglobular proteinlight scatteringmacromoleculemortalitynon-smokernon-smokingpathogenpatient populationpreventprotein complex
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chronic lung diseases such as COPD are characterized by a hypersecretion of mucus, which often exacerbates morbidity and hastens mortality. A characteristic of these diseases is that they are often accompanied by mucus stasis and enhanced susceptibility to infection and inflammation. Airway mucins, particularly MUC5AC and MUC5B, are the major constituent of the mucus gel and play an important role in the mucociliary clearance. Over a hundred other proteins contribute mucus structure, of which approximately half are associated with mucins in some fashion, according to recent proteomic studies done in our laboratory. There are very few studies investigating the mucin/mucus composition in COPD, and those that have been published are based on very small populations of patients. Additionally, we do not know whether COPD mucus pathology results from a simple accumulation of "normal" mucus, or whether the mucus has an abnormal mucin composition and/or properties. Our overall hypothesis, based upon our previous and ongoing studies, is that the molecular composition of the mucus and the concentration and macromolecular organization of its mucins are altered in the COPD environment -- both in baseline and during exacerbations. These alterations produce a mucus that has an aberrant rheology, that is poorly transportable by normal ciliary and cough clearance mechanisms. In testing these hypotheses, using a broad range of biochemical, biophysical and proteomics methods, we propose to assess, [i] mucin concentration and the ratio of MUC5AC/MUC5B, [ii] the effects of proteolysis on overall mucin polymeric structure, and [iii] the dynamic interplay between mucins and interacting proteins, using samples of mucus obtained through "Subpopulations and intermediate outcome measures in COPD study" (SPIROMICS), from normal controls, healthy smokers, and COPD patients, both at baseline and exacerbation. At the broadest level, the major scientific goal of this proposal is to compare the measured parameters over a large number of normal controls and COPD patients, and within the patient population, to enable the sub-classifications of COPD patients and discovery of biomarkers, consistent with the main goals of SPIROMICS. The proposed studies are needed to achieve a more integrated view and thus more rational approaches for designing effective therapeutic modalities to the treatment of hypersecretory states such as COPD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core B: Mucus/Mucin Analytics Core
-
批准号:10684187
-
项目类别:
-
资助金额:$26.83万
-
财政年份:2022
-
负责人:Mehmet Kesimer
-
依托单位:
The effect of Inhaled Nicotine on Pulmonary Surfaces
-
批准号:10083514
-
项目类别:
-
资助金额:$6.29万
-
财政年份:2020
-
负责人:Mehmet Kesimer
-
依托单位:
The effect of Inhaled Nicotine on Pulmonary Surfaces
-
批准号:10089471
-
项目类别:
-
资助金额:$55.72万
-
财政年份:2017
-
负责人:Mehmet Kesimer
-
依托单位:
The effect of Inhaled Nicotine on Pulmonary Surfaces
-
批准号:9234295
-
项目类别:
-
资助金额:$45.6万
-
财政年份:2017
-
负责人:Mehmet Kesimer
-
依托单位:
Core B: Analytics for Mucolytics Core
-
批准号:10001595
-
项目类别:
-
资助金额:$32.19万
-
财政年份:2017
-
负责人:Mehmet Kesimer
-
依托单位:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
-
批准号:8521361
-
项目类别:
-
资助金额:$35.22万
-
财政年份:2011
-
负责人:Mehmet Kesimer
-
依托单位:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
-
批准号:8215467
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2011
-
负责人:Mehmet Kesimer
-
依托单位:
Airway mucus/mucin composition and proteome in COPD: A SPIROMICS ancillary study
-
批准号:8688051
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2011
-
负责人:Mehmet Kesimer
-
依托单位:
The role of mucin-protein interactions in the innate defense of the lung
-
批准号:8656401
-
项目类别:
-
资助金额:$35.9万
-
财政年份:2010
-
负责人:Mehmet Kesimer
-
依托单位:
The role of mucin-protein interactions in the innate defense of the lung
-
批准号:8116579
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2010
-
负责人:Mehmet Kesimer
-
依托单位:
The role of mucin-protein interactions in the innate defense of the lung
-
批准号:8252157
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2010
-
负责人:Mehmet Kesimer
-
依托单位:
The role of mucin-protein interactions in the innate defense of the lung
-
批准号:7946676
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2010
-
负责人:Mehmet Kesimer
-
依托单位:
The role of mucin-protein interactions in the innate defense of the lung
-
批准号:8463602
-
项目类别:
-
资助金额:$34.87万
-
财政年份:2010
-
负责人:Mehmet Kesimer
-
依托单位:
Project 1: The Effects of New and Emerging Tobacco Products on Lung Hyd
-
批准号:9328120
-
项目类别:
-
资助金额:$57.44万
-
财政年份:--
-
负责人:Mehmet Kesimer
-
依托单位:
Project 1: The Effects of New and Emerging Tobacco Products on Lung Hyd
-
批准号:8595538
-
项目类别:
-
资助金额:$65.27万
-
财政年份:--
-
负责人:Mehmet Kesimer
-
依托单位:
Project 1: The Effects of New and Emerging Tobacco Products on Lung Hyd
-
批准号:8737947
-
项目类别:
-
资助金额:$57.27万
-
财政年份:--
-
负责人:Mehmet Kesimer
-
依托单位:
海外基金